What do the clinical studies show about the efficacy, recommended dosing, and safety of elinzanetant for treating moderate-to-severe vasomotor symptoms in postmenopausal women?

Elinzanetant for Moderate-to-Severe Vasomotor Symptoms in Postmenopausal Women

Elinzanetant (LYNKUET) 120 mg once daily at bedtime is an effective and FDA-approved nonhormonal treatment for moderate-to-severe vasomotor symptoms in postmenopausal women, demonstrating statistically significant and clinically meaningful reductions in both frequency and severity of hot flashes starting as early as week 1, with sustained benefits through 52 weeks. 1

Mechanism and Pharmacology

Elinzanetant is the first dual neurokinin-1 (NK-1) and neurokinin-3 (NK-3) receptor antagonist, targeting hypothalamic thermoregulatory pathways involved in vasomotor symptom generation. This distinguishes it mechanistically from selective NK-3 antagonists like fezolinetant. 2, 3

Clinical Efficacy

Frequency Reduction

The pivotal OASIS-1 and OASIS-2 trials (N=796 postmenopausal women with ≥50 moderate-to-severe hot flashes per week) demonstrated:

• Week 4: Reduction of 7.60 and 8.58 hot flashes/day vs. 4.31 and 5.54 with placebo (difference: -3.29 and -3.04, p<0.0001) 1
• Week 12: Reduction of 8.66 and 9.72 hot flashes/day vs. 5.44 and 6.48 with placebo (difference: -3.22 and -3.24, p<0.0001) 1
• Benefits appeared as early as week 1 and were maintained through 52 weeks 4

Severity Reduction

Both trials showed statistically significant reductions in vasomotor symptom severity at weeks 4 and 12 compared to placebo (p<0.0001). 1

Comparative Efficacy

Network meta-analysis demonstrated elinzanetant's superiority or comparability to other nonhormonal treatments:

• Superior to: Paroxetine 7.5 mg (MD: -2.11 hot flashes/day), desvenlafaxine 50-200 mg (MD: -2.77 to -1.72), and gabapentin 1200-1800 mg (MD: -2.22 to -2.31) 5
• Comparable to: Fezolinetant 45 mg and desvenlafaxine 150 mg for ≥50% responder rates 5

Sleep and Quality of Life

• Significant improvements in PROMIS Sleep Disturbance scores at week 12 across all OASIS trials 4
• Superior reduction in nighttime awakenings compared to paroxetine and all desvenlafaxine regimens 5
• Improved menopause-specific quality of life (MENQoL) scores 4

Recommended Dosing

Standard dose: 120 mg (two 60 mg capsules) orally once daily at bedtime 1

Dosing Modifications

• Moderate CYP3A4 inhibitors: Reduce to 60 mg once daily; resume 120 mg after 3-5 half-lives post-discontinuation 1
• Strong CYP3A4 inhibitors or grapefruit: Avoid concomitant use 1
• Strong/moderate CYP3A4 inducers: Avoid concomitant use 1

Administration

• Take with or without food
• Swallow capsules whole with water (do not cut, crush, or chew)
• If dose missed at bedtime, skip and resume next scheduled dose 1

Safety Profile

Common Adverse Events

Meta-analysis of 1,699 participants showed elinzanetant was associated with higher incidence of:

• Headache (RR=2.19, p=0.0009) 6
• Somnolence (RR=2.96, p=0.004) 6
• Fatigue (RR=3.39, p=0.0002) 6
• Drug-related TEAEs (RR=1.92, p<0.00001) 6

Serious Adverse Events

No significant increase in serious adverse events compared to placebo (RR=1.70, p=0.15), indicating an acceptable safety profile. 6

CNS Effects and Precautions

Nervous system effects (somnolence, fatigue, vertigo, dizziness, presyncope) occurred in 11.9% vs. 3.5% with placebo. Patients experiencing these effects should refrain from driving or hazardous activities until resolved. 1

Discontinuation Rates

Treatment discontinuation due to adverse events was higher with elinzanetant (RR=2.18, p=0.0002), primarily driven by CNS effects and headache. 6

Pre-Treatment Requirements

Before initiating elinzanetant:

1. Exclude pregnancy in women of reproductive potential (contraindicated in pregnancy due to risk of pregnancy loss/stillbirth) 1
2. Baseline hepatic function tests: ALT, AST, alkaline phosphatase, total and direct bilirubin 1
3. Do not start if: ALT or AST ≥2× ULN, or total bilirubin ≥2× ULN 1

Special Populations

Breast Cancer Patients

OASIS-4 demonstrated consistent efficacy and safety in women receiving endocrine therapy for breast cancer, with similar reductions in vasomotor symptoms and improvements in sleep disturbance. 4

Long-Term Use

Efficacy and tolerability were maintained through 52 weeks of treatment across all OASIS trials. 4

Clinical Context

While hormone therapy remains the most effective treatment for vasomotor symptoms per established guidelines 7, it carries contraindications including breast cancer history, thromboembolic disease, stroke, and active liver disease 7. Elinzanetant provides a critical nonhormonal alternative for women who cannot or prefer not to use hormone therapy, with efficacy superior to other nonhormonal options like SSRIs, SNRIs, and gabapentin. 5, 3

Common Pitfalls to Avoid

• Do not use with strong CYP3A4 inhibitors without dose adjustment or avoidance 1
• Counsel patients about CNS effects before initiating, particularly regarding driving and hazardous activities 1
• Monitor hepatic function at baseline; do not initiate if transaminases or bilirubin are significantly elevated 1
• Ensure pregnancy exclusion in women of reproductive potential before starting 1
• Take at bedtime to minimize daytime somnolence impact 1